Lioresal Intrathecal 10 mg/20 ml

Leaflet attached to the packaging: information for the user

Warning! Keep the leaflet! Information on the immediate packaging in a foreign language.

Lioresal Intrathecal 10 mg/20 ml, solution for infusion

For use in adult and pediatric patients 4 years of age and older
Baclofen

Read the leaflet carefully before using the medicine, as it contains important information for the patient.

• Keep this leaflet, so you can read it again if you need to.
• If you have any doubts, consult a doctor or pharmacist.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
• If you experience any side effects, including any possible side effects not listed in this leaflet, tell your doctor or pharmacist. See section 4.

Table of contents of the leaflet

• 1. What is Lioresal Intrathecal 10 mg/20 ml and what is it used for
• 2. Important information before using Lioresal Intrathecal 10 mg/20 ml
• 3. How to use Lioresal Intrathecal 10 mg/20 ml
• 4. Possible side effects
• 5. How to store Lioresal Intrathecal 10 mg/20 ml
• 6. Contents of the packaging and other information

1. What is Lioresal Intrathecal 10 mg/20 ml and what is it used for

Lioresal Intrathecal 10 mg/20 ml contains the active substance baclofen.
Lioresal Intrathecal 10 mg/20 ml is a medicine used for excessive muscle tension.
Lioresal Intrathecal 10 mg/20 ml is used to treat severe, chronic spasticity
(increased muscle tone)that cannot be effectively treated with standard medicines:

• in multiple sclerosis This is a progressive disease of the nervous system, brain, and spinal cord with physical and mental symptoms.
• after spinal cord injuries or injuries with brain damage
• in other spinal cord diseases

During the qualification phase for treatment and during the dose-increase phase, immediately after pump implantation, the patient will be closely monitored in conditions that ensure access to appropriate equipment and staff care. Dosing, possible side effects, or signs of infection will be regularly evaluated. The functioning of the drug delivery system will also be checked.
If there is no improvement or the patient feels worse, they should consult a doctor.

2. Important information before using Lioresal Intrathecal 10 mg/20 ml

When not to use Lioresal Intrathecal 10 mg/20 ml

• if the patient is allergic to baclofenor any of the other ingredients of this medicine (listed in section 6). If the patient thinks they may be allergic, they should consult a doctor

doctor

• if the patient has untreatable epilepsy.

Warnings and precautions

Consult a doctor immediately if the patient thinks the device is not working properly or if they notice withdrawal symptoms (see withdrawal symptoms in section 3 "How to use Lioresal Intrathecal 10 mg/20 ml").
If any of the following points apply to the patient, they should tell their doctor before starting treatment with Lioresal Intrathecal 10 mg/20 ml:

• circulation disorders of cerebrospinal fluid due to obstruction
• treatable epilepsy or other seizures affecting the brain
• neurological disorders caused by damage to cranial nerves in the spinal cord (symptoms of bulbar palsy) or partial paralysis of respiratory muscles
• acute or chronic confusion
• psychiatric and/or psychological disorders, such as schizophrenia
• Parkinson's disease
• autonomic reflex disorders (uncontrolled) in history
• insufficient blood flow to the brain
• breathing difficulties
• overactive bladder sphincter
• heart disease
• kidney function disorders
• stomach and intestinal ulcers
• severe liver function disorders
• increased muscle tone due to a previous head injury. Long-term treatment of increased muscle tone should be started when spasticity symptoms are stable and can be reliably assessed.

If any of these symptoms occur during treatment with Lioresal Intrathecal 10 mg/20 ml, the patient should immediately inform their doctor:

• If the patient experiences back, arm, neck, and buttock pain during treatment (a type of spinal deformity called scoliosis).
• If the patientever thinks about self-harm or suicide, they should immediately talk to a doctor or go to the hospital. They should also ask a relative or close friend to inform them if they notice changes in their behavior and read this leaflet.

Children
The following requirements should be met for children regarding suitable body weight to allow for pump implantation. Lioresal Intrathecal 10 mg/20 ml is intended for use in children 4 years of age and older. The safety of intrathecal use of Lioresal Intrathecal 10 mg/20 ml in children under 4 years of age has not been established yet.
Patient over 65 years old
During clinical trials, Lioresal Intrathecal 10 mg/20 ml was administered to several elderly patients and did not cause particular problems. However, experience with the use of Lioresal in tablet form shows that this group of patients may be more prone to side effects. Therefore, elderly patients should be closely monitored for side effects.

Lioresal Intrathecal 10 mg/20 ml and other medicines

Tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
The following medicines may affect the action of Lioresal Intrathecal 10 mg/20 ml or Lioresal Intrathecal 10 mg/20 ml may interact with them. It may be necessary to adjust the dose of Lioresal Intrathecal 10 mg/20 ml or one of the other medicines taken at the same time:

• medicines used in Parkinson's disease
• medicines that relieve severe muscle spasms
• medicines with a sedating effect on the central nervous system
• medicines used to treat depression, such as imipramine, doxepin, amitriptyline, opipramol
• medicines used to treat high blood pressure.

Lioresal Intrathecal 10 mg/20 ml with food, drink, and alcohol

When using Lioresal Intrathecal 10 mg/20 ml, you should avoid consuming alcohol at the same time, as it may cause unwanted intensification or unpredictable changes in the action of the medicine.

Pregnancy and breastfeeding

Due to the lack of experience, pregnant and breastfeeding women may use Lioresal Intrathecal 10 mg/20 ml only if the doctor considers it absolutely necessary.

Driving and using machines

Do not drive vehicles, operate machinesor perform other hazardous activities, as Lioresal Intrathecal 10 mg/20 ml may significantly affect these activities.

Lioresal Intrathecal 10 mg/20 ml contains sodium

The medicine contains 70.81 mg of sodium (main component of table salt) per 20 ml. This corresponds to 3.5% of the maximum recommended daily sodium intake in the diet for adults.

3. How to use Lioresal Intrathecal 10 mg/20 ml

This medicine should always be used as directed by your doctor. If you are unsure, consult your doctor or pharmacist.
Lioresal Intrathecal 10 mg/5 ml and Lioresal Intrathecal 10 mg/20 ml are available on the market.

Method of administration

Lioresal Intrathecal 10 mg/20 ml can be administered by direct injection or infusion into the spinal canalonly by a qualified specialist and with the help of appropriate equipment.
Therefore, hospitalization is necessary at the beginning of treatment.
At the beginning of treatment, the doctor will determine whether a single injection of the medicine in a smaller dose - Lioresal Intrathecal, 0.05 mg/1 ml, solution for injection - will relieve muscle spasms. If possible, a special pump will be implanted under the patient's skin, which will allow for continuous dosing tailored to the patient.
It is very important for the patient to attend scheduled appointments, during which the doctor will refill the pump.
If the patient receives too small a dose of Lioresal Intrathecal 10 mg/20 ml, increased muscle tone may return. Muscle spasms may also worsen.
Tell your doctor immediatelyif muscle spasms do not improve or worsen.
The doctor must regularly monitor the patient's condition and the pump's function - at least once a month.

Duration of treatment

The duration of treatment will be decided by your doctor.

Using a higher dose of Lioresal Intrathecal 10 mg/20 ml than recommended

Immediately contact your doctorif you or your caregiver notice symptoms of overdose, which can occur suddenly or gradually:

• too little muscle tone
• drowsiness
• dizziness or feeling of emptiness in the head
• excessive salivation
• nausea or vomiting
• breathing difficulties or even respiratory arrest
• seizures
• reduced consciousness or even coma
• low body temperature.

Stopping treatment with Lioresal Intrathecal 10 mg/20 ml

If it is necessary to stop the administration of the medicine, it can only be done by the attending physician, who will gradually reduce the dose of the medicine to avoid side effects. Abrupt cessation of Lioresal Intrathecal 10 mg/20 ml may cause severe side effects, which in several cases have been fatal.
Immediately contact your doctorif you or your caregiver notice the following symptoms and signs of withdrawalfrom Lioresal Intrathecal 10 mg/20 ml. This is especially important for further administration through the pump.

• increased spasticity, too much muscle tone
• difficulty moving muscles
• increased heart rate and faster pulse
• itching
• tingling, burning, or numbness of hands and feet
• palpitations
• anxiety
• fever
• low blood pressure
• changes in the patient's mental state, such as agitation, disorientation, hallucinations, abnormal thinking, and behavior
• seizures
• prolonged painful erection of the penis (priapism) The above symptoms can cause more severe side effects, which can lead to death if not treated immediately.

Remember that pump malfunctions, such as battery problems or catheter problems, alarm signal defects, or device malfunction, can lead to overdose or underdose of the medicine.
If you have any doubts about using the medicine, consult your doctor.

4. Possible side effects

*Side effects marked with an asterisk occur more frequently in patients with
cerebral palsy.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Side effects are more common during the initiation of treatment in the hospital, but they can also occur later. Many of the listed side effects may also be related to the underlying disease being treated.
Malfunction of the implanted device delivering the medicine or the infusion system can lead to withdrawal symptoms, which can be life-threatening (see withdrawal symptoms in section 3 "How to use Lioresal Intrathecal 10 mg/20 ml").
The following side effects have been reported, along with their frequency:

• low muscle tone
• drowsiness

Very common: may occur in more than 1 in 10 patients

• anxiety
• decreased appetite
• shortness of breath, slow or shallow breathing
• decreased alertness
• decreased blood pressure when sitting and standing
• depression
• disorientation
• diarrhea, even incontinence of feces
• increased muscle tone
• fever
• increased restlessness
• urinary retention*
• itchy skin swelling, similar to an insect bite
• itching
• headache*, pain
• seizures*
• pneumonia
• strange skin sensations with tingling of hands and feet
• dry mouth
• muscle weakness
• coma
• chills
• swelling of the face, hands, and feet
• dizziness
• sexual disorders
• vision disorders with blurred or double vision
• apathy
• involuntary urination
• nausea or vomiting*
• excessive salivation
• constipation
• slurred speech
• confusion
• respiratory depression

Uncommon: may occur in fewer than 1 in 100 patients

• decreased fluid in the body (dehydration)
• pale skin
• high blood pressure
• intestinal obstruction due to blockage
• memory loss/confusion
• mood disorders
• hair loss
• false sensory perceptions not caused by an external stimulus
• skin redness
• low body temperature
• difficulty swallowing
• coordination problems
• suicidal thoughts and attempts
• excessive sweating
• slow heart rate
• reduced sense of taste
• blockage of a blood vessel due to a blood clot in the deep veins
• hallucinations
• euphoria

Rare: may occur in fewer than 1 in 1,000 patients

• life-threatening withdrawal symptoms due to administration problems

Some side effects occur with an unknown frequency:

• increase in lateral curvature of the spine (scoliosis)
• inability to achieve or maintain an erection (erectile dysfunction)

Reporting side effects

If you experience any side effects, including any possible side effects not listed in this leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181 C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help gather more information on the safety of the medicine.

5. How to store Lioresal Intrathecal 10 mg/20 ml

Keep the medicine out of sight and reach of children.

Storage conditions

Do not store above 30°C.
Do not freeze. Do not sterilize with high temperature.
The medicine should be used immediately after opening. Unused solution should be discarded.
The solution must be clear and colorless. Do not use this medicine if you notice turbidity or discoloration.
Do not use Lioresal Intrathecal 10 mg/20 ml after the expiry date stated on the packaging. The expiry date refers to the last day of the specified month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

• The active substance of the medicine is baclofen.

1 ml of the solution for infusion contains 0.5 mg of baclofen.
1 ampoule with 20 ml of the solution for infusion contains 10 mg of baclofen.

• The other ingredients are: sodium chloride, water for injections.

What Lioresal Intrathecal 10 mg/20 ml looks like and what the packaging contains

Lioresal Intrathecal 10 mg/20 ml is a clear, colorless solution in a transparent, colorless ampoule.
Lioresal Intrathecal 10 mg/20 ml solution for infusion is available in packs containing 1, 2, or 5 ampoules.
For more detailed information, please contact the marketing authorization holder or the parallel importer.

Marketing authorization holder in Germany, the country of export:

Novartis Pharma GmbH
Roonstr. 25
D-90429 Nuremberg
Germany

Manufacturer:

Novartis Pharma GmbH
Roonstr. 25
D-90429 Nuremberg
Germany

Parallel importer:

InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw

Repackaged by:

Pharma Innovations Sp. z o.o.
ul. Jagiellońska 76
03-301 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Authorization number in Germany, the country of export:39917.01.01
Parallel import authorization number:282/19

This medicinal product has been authorized in the Member States of the European Economic Area under the following names:

Germany:
Lioresal Intrathecal 10 mg/20 ml Infusionslösung
Poland:
Lioresal Intrathecal 10 mg/20 ml, solution for infusion

Date of leaflet approval: 12.07.2024

[Information about the trademark]

Information intended only for healthcare professionals:

How to prepare and administer the medicinal product Lioresal Intrathecal 10 mg/20 ml?

The administration of a test dose, implantation of the infusion pump, and dose increase of the intrathecally administered medicinal product should be performed in a hospital setting, in centers with appropriate experience and under the close supervision of qualified physicians. Immediate access to an intensive care unit should be ensured due to the possibility of severe or life-threatening side effects of the medicinal product.
To determine the optimal dosing schedule for Lioresal Intrathecal 10 mg/20 ml, each patient first receives a test dose of Lioresal Intrathecal 0.05 mg/1 ml by intrathecal injection in a bolus through a spinal catheter or lumbar puncture. Then, the dose is carefully adjusted individually to the patient's needs. This is necessary due to significant differences in therapeutically effective doses for individual patients.
In long-term therapy, Lioresal Intrathecal 10 mg/20 ml is administered using an implanted pump that allows for continuous infusion of the baclofen solution into the cerebrospinal fluid.
The antispastic effect of baclofen begins within 6 to 8 hours after the start of continuous infusion and reaches its maximum within 24 to 48 hours.
The initial total daily dose of Lioresal Intrathecal 10 mg/20 ml is calculated as follows: if the effect of the test dose lasts more than 12 hours, this dose is used as the initial dose. If the effect of the test dose lasts less than 12 hours, the test dose is doubled and used as the initial dose. The dose should not be increased within the first 24 hours of treatment.
After the first day of treatment, the dose can be gradually increased to achieve the desired therapeutic effect. The daily dose should not be increased by more than 10% to 30% of the previous dose in patients with spinal spasticity and 5% to 15% in patients with cerebral spasticity. When using a programmable pump, it is recommended to modify the dose only once every 24 hours. When using non-programmable pumps equipped with a 76 cm catheter, delivering 1 ml of solution per day, it is recommended to assess the patient's response to the new dose after 48 hours. If a significant increase in the daily dose does not result in increased clinical efficacy, the proper functioning of the pump and catheter patency should be checked.
Essentially, the dose of Lioresal Intrathecal 10 mg/20 ml is increased to achieve a maintenance dose in the range of 300 µg to 800 µg per day in patients with spinal spasticity. Patients with cerebral spasticity usually require lower doses (see below).

Long-term therapy phase

The goal of treatment is to use the smallest dose that provides good control of spasticity without unacceptable side effects. Since the therapeutic effect may decrease during treatment, and the severity of spasticity may change, it is usually necessary to adjust the dose in the long-term therapy phase.
Also, in this case, the daily dose can be increased by 10% to 30% in patients with spinal spasticity and 5% to 20% (upper limit) in patients with cerebral spasticity by changing the infusion rate or the concentration of baclofen in the pump reservoir. And vice versa, if side effects occur, the daily dose of Lioresal Intrathecal 10 mg/20 ml can be decreased by 10% to 20%.
The need for rapid dose increase to achieve the desired therapeutic effect suggests possible pump malfunction or catheter kinking, cracking (abrasion), or displacement.
The maintenance dose of Lioresal Intrathecal 10 mg/20 ml in long-term therapy in patients with spinal spasticity is usually 300 µg to 800 µg of baclofen per day. The lowest and highest registered daily doses administered to individual patients during the loading phase were 12 µg and 2003 µg (studies conducted in the United States). Experience with doses exceeding 1000 µg per day is limited. During the first few months of treatment, it is necessary to verify the dose of Lioresal Intrathecal 10 mg/20 ml and modify it, especially frequently.
In patients with cerebral spasticity, the maintenance doses used during long-term therapy with continuous infusion of Lioresal Intrathecal 10 mg/20 ml are in the range of 22 µg to 1400 µg of baclofen per day, and the average daily doses are 276 µg after 1 year of observation and 307 µg after 2 years. Children under 12 years of age usually require lower doses (range: 24 µg to 1199 µg per day; average: 274 µg per day).
If the pump's technical parameters allow, after determining the daily dose and stabilizing the antispastic effect, it is possible to try to adjust the administration of the medicinal product to the daily rhythm of spasticity. For example, if spasms occur more frequently at night, this may require a 20% increase in the infusion rate for one hour. Changes in the infusion rate should be programmed to occur 2 hours before the desired clinical effect.
Throughout the treatment period, regular, at least monthly, monitoring of tolerance to Lioresal Intrathecal 10 mg/20 ml and possible signs of infection is necessary in the treatment center. The proper functioning of the infusion system should be regularly checked. The development of local infection or catheter malfunction can lead to interruption of intrathecal administration of Lioresal Intrathecal 10 mg/20 ml with life-threatening consequences for the patient.
The concentration of baclofen required during pump filling depends on the total daily dose of the medicinal product and the infusion rate of the pump. If it is necessary to administer baclofen in concentrations other than 0.05 mg/ml, 0.5 mg/ml, or 2 mg/ml, Lioresal Intrathecal 10 mg/20 ml should be diluted under aseptic conditions using a sterile sodium chloride solution for injectionwithout preservatives. In this case, follow the instructions provided by the pump manufacturer.

Pump implantation / dose-increase phase (in a hospital setting)

After confirming the patient's response to Lioresal Intrathecal 10 mg/20 ml in the test phase, intrathecal infusion of the medicinal product can be started using the above-mentioned infusion pump. The antispastic effect of baclofen begins within 6 to 8 hours after the start of continuous infusion, and the maximum effect is observed within 24 to 48 hours.
The initial total daily dose of Lioresal Intrathecal 10 mg/20 ml is calculated as follows: if the effect of the test dose lasts more than 12 hours, this dose is used as the initial dose. If the effect of the test dose lasts less than 12 hours, the test dose is doubled and used as the initial dose. The dose should not be increased within the first 24 hours of treatment.
After the first day of treatment, the dose can be gradually increased to achieve the desired therapeutic effect. The daily dose should not be increased by more than 10% to 30% of the previous dose in patients with spinal spasticity and 5% to 15% in patients with cerebral spasticity. When using a programmable pump, it is recommended to modify the dose only once every 24 hours. When using non-programmable pumps equipped with a 76 cm catheter, delivering 1 ml of solution per day, it is recommended to assess the patient's response to the new dose after 48 hours. If a significant increase in the daily dose does not result in increased clinical efficacy, the proper functioning of the pump and catheter patency should be checked.

Long-term therapy phase

The goal of treatment is to use the smallest dose that provides good control of spasticity without unacceptable side effects. Since the therapeutic effect may decrease during treatment, and the severity of spasticity may change, it is usually necessary to adjust the dose in the long-term therapy phase.
Also, in this case, the daily dose can be increased by 10% to 30% in patients with spinal spasticity and 5% to 20% (upper limit) in patients with cerebral spasticity by changing the infusion rate or the concentration of baclofen in the pump reservoir. And vice versa, if side effects occur, the daily dose of Lioresal Intrathecal 10 mg/20 ml can be decreased by 10% to 20%.
The need for rapid dose increase to achieve the desired therapeutic effect suggests possible pump malfunction or catheter kinking, cracking (abrasion), or displacement.
The maintenance dose of Lioresal Intrathecal 10 mg/20 ml in long-term therapy in patients with spinal spasticity is usually 300 µg to 800 µg of baclofen per day. The lowest and highest registered daily doses administered to individual patients during the loading phase were 12 µg and 2003 µg (studies conducted in the United States). Experience with doses exceeding 1000 µg per day is limited. During the first few months of treatment, it is necessary to verify the dose of Lioresal Intrathecal 10 mg/20 ml and modify it, especially frequently.
In patients with cerebral spasticity, the maintenance doses used during long-term therapy with continuous infusion of Lioresal Intrathecal 10 mg/20 ml are in the range of 22 µg to 1400 µg of baclofen per day, and the average daily doses are 276 µg after 1 year of observation and 307 µg after 2 years. Children under 12 years of age usually require lower doses (range: 24 µg to 1199 µg per day; average: 274 µg per day).
If the pump's technical parameters allow, after determining the daily dose and stabilizing the antispastic effect, it is possible to try to adjust the administration of the medicinal product to the daily rhythm of spasticity. For example, if spasms occur more frequently at night, this may require a 20% increase in the infusion rate for one hour. Changes in the infusion rate should be programmed to occur 2 hours before the desired clinical effect.
Throughout the treatment period, regular, at least monthly, monitoring of tolerance to Lioresal Intrathecal 10 mg/20 ml and possible signs of infection is necessary in the treatment center. The proper functioning of the infusion system should be regularly checked. The development of local infection or catheter malfunction can lead to interruption of intrathecal administration of Lioresal Intrathecal 10 mg/20 ml with life-threatening consequences for the patient.
The concentration of baclofen required during pump filling depends on the total daily dose of the medicinal product and the infusion rate of the pump. If it is necessary to administer baclofen in concentrations other than 0.05 mg/ml, 0.5 mg/ml, or 2 mg/ml, Lioresal Intrathecal 10 mg/20 ml should be diluted under aseptic conditions using a sterile sodium chloride solution for injectionwithout preservatives. In this case, follow the instructions provided by the pump manufacturer.

Incompatibilities

Lioresal Intrathecal 10 mg/20 ml solution for infusion should not be mixed with other solutions for injection or infusion, except for sterile, preservative-free sodium chloride solution, diluted under aseptic conditions.
A chemical incompatibility has been demonstrated between dextrose and baclofen.
Do not freeze. Do not sterilize with high temperature.